Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

被引:6
|
作者
Zeng, Li [1 ]
Ma, Gang [2 ,3 ]
Chen, Kai [1 ]
Zhou, Qiao [3 ,4 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Neurol, Chengdu, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immune checkpoint inhibitor; rheumatic immune-related adverse event; bibliometric; research trends; VOSviewer; CiteSpace; INDUCED SARCOIDOSIS; TUMOR RESPONSE; IMMUNOTHERAPY; AUTOIMMUNITY; NIVOLUMAB; BLOCKADE; ANTIBODY; CTLA4;
D O I
10.3389/fimmu.2023.1242336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods.Methods The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined.Results In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to "monoclonal antibody," "anti-CLTA4 antibody," and "melanoma". This was followed by a rise in interest related to "sarcoidosis," "safety," "inflammatory arthritis," and "preexisting autoimmune."Conclusion This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors
    Campochiaro, Corrado
    Farina, Nicola
    Tomelleri, Alessandro
    Ferrara, Roberto
    Viola, Silvia
    Lazzari, Chiara
    De Luca, Giacomo
    Raggi, Daniele
    Bulotta, Alessandra
    Matucci-Cerinic, Marco
    Necchi, Andrea
    Garassino, Marina
    Gregorc, Vanesa
    Dagna, Lorenzo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 103 : 95 - 99
  • [42] PHYSICIAN AWARENESS OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
    Araujo, F.
    Fonseca, J. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1777 - 1778
  • [43] A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
    Jessica Castrillon Lal
    Sherry-Ann Brown
    Patrick Collier
    Feixiong Cheng
    Cardio-Oncology, 7
  • [44] A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
    Lal, Jessica Castrillon
    Brown, Sherry-Ann
    Collier, Patrick
    Cheng, Feixiong
    CARDIO-ONCOLOGY, 2021, 7 (01)
  • [45] Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
    Zhang, Shuo
    Zhou, Ziyue
    Wang, Li
    Li, Mengtao
    Zhang, Fengchun
    Zeng, Xiaofeng
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
  • [46] RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES FROM TWO REFERRAL CENTRES
    Rodriguez-Garcia, Sebastian C.
    Lobo, David
    Castellanos-Moreira, Raul
    Millan Arciniegas, Ana Milena
    Gumucio, Roberto
    Laiz, Ana
    Ruiz-Esquide, Virginia
    Magallares, Berta
    Diaz-Torne, Cesar
    Moya, Patricia
    Castellvi, Ivan
    Corominas, Hector
    Gomez-Puerta, Jose A.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 991 - 991
  • [47] Predictors of immune-related adverse events associated with checkpoint inhibitors.
    Alsayed, Alhareth
    Manne, Ashish
    Escobar, Daisy E.
    Sharma, Gaurav
    Prodduturvar, Pranitha
    Alkharabsheh, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
    Postow, Michael A.
    Sidlow, Robert
    Hellmann, Matthew D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 158 - 168
  • [49] Retrospective Analysis of Immune Checkpoint Inhibitors in NSCLC: Immune-Related Adverse Events and Outcomes
    Lee, A.
    Luong, M.
    Ohana, D.
    Forster, M.
    Lee, S. M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S734 - S735
  • [50] Adverse Events of Immune Checkpoint Inhibitors
    Foller, S.
    Oppel-Heuchel, H.
    Fetter, I.
    Winkler, Y.
    Grimm, M. -O.
    UROLOGE, 2017, 56 (04): : 486 - 491